Polymyalgia Rheumatica Treatment Market By Based on Diagnostic Method (Blood Tests, Imaging Tests), Based on Drug Class (Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs), By Application (Hospitals, Homecare, Specialty Clinics) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032
- account_circleAbout Me
- 77467
-
US $6,000US $3,999
-
US $8,000US $5,999
-
US $10,000US $6,999
Introduction
Polymyalgia Rheumatica (PMR) is an inflammatory condition that produces muscle pain and stiffness in the neck, hips, shoulders, thighs, and arms. Polymyalgia is a phrase derived from the Greek word "myalgia," which means "muscle pain." Pain in numerous bodily sections is referred to as polymyalgia. This disorder is more common in adults over the age of 60. Females are more likely than males to develop it, with a 2:1 ratio. The condition develops over a period of time in some individuals, whereas it occurs overnight in others. Giant Cell Arteritis (GCA) is frequently associated with polymyalgia rheumatic. This illness causes the arteries in the head to enlarge, causing impaired vision and headaches.
Although the specific etiology of the disease is unknown, it is thought that interactions between numerous elements such as autoimmunity, genetic predispositions, and viral infections may contribute to this disease's emergence. Autoimmunity occurs when an individual's immune cells attack joints and connective tissue, resulting in polymyalgia rheumatica. According to reports, genetic factors enhance the risk of contracting this condition. According to certain studies, people with the HLA-DR4 haplotype had a higher risk of PMR. Furthermore, those of Scandinavian and northern European origin are particularly vulnerable to PMR. Polymyalgia rheumatica is sometimes caused by viral infections. Some viruses, such as the human parainfluenza virus, adenovirus, and parvovirus B19, have been implicated in PMR.
Detailed Segmentation
Based on Diagnostic Method:
- Blood Tests
- Imaging Tests
Based on Drug Class:
- Corticosteroids
- Disease-Modifying Anti-Rheumatic Drugs
- Non-Steroidal Anti-Inflammatory Drugs
Based on Route of Administration:
- Oral
- Parenteral
Based on End-Use:
- Hospitals
- Homecare
- Specialty Clinics
Based on Region:
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Market Dynamics
Drivers for the Global Polymyalgia Rheumatica Treatment Market:
The increased implementation of improved diagnostic technology is fueling the global polymyalgia rheumatica market. Owing to an increase in the number of studies and research on polymyalgia rheumatic symptoms, this market is expected to further develop. Additionally, the use of sophisticated diagnostic technologies to analyze shoulder subacromial and subdeltoid bursitis, hip synovitis, and iliopectineal bursitis to create effective treatments are expected to augment this market’s economic growth.
Restraints Global Polymyalgia Rheumatica Treatment Market:
There are currently no particular tests for the diagnosis of polymyalgia rheumatica, thus clinicians must rely on a mix of history, physical examination, laboratory tests, and imaging studies to determine an accurate diagnosis.
Opportunities for the Global Polymyalgia Rheumatica Treatment Market:
Rapid technical breakthroughs in technologies like Magnetic Resonance Imaging (MRI) are helping to reduce the risk of errors and contribute to a faster and more accurate diagnosis of this condition. Physical therapy is gaining popularity among customers owing to its high effectiveness and the lack of adverse effects.
Trends for the Global Polymyalgia Rheumatica Treatment Market:
Physiotherapies are individualized treatments that aim to alleviate muscle stiffness and enhance muscle strength dependent on the severity of this condition. Therefore, variables are expected to have a large impact on this market revenue growth over the forecast period.
Competitive Landscape
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc.
- Mayo Foundation for Medical Education and Research (MFMER)
- Cleveland Clinic
- Arthritis Foundation
- Healthily
- Physio.co.uk
- Sparrow Health Systems
For the Polymyalgia Rheumatica Treatment Market research study, the following years have been considered to estimate the market size:
Particular Scope Region - North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Historic Year 2016 to 2020 Estimated Year 2022 Forecast Year 2023 to 2032 - account_circleAbout Me
- 77467
-
US $6,000US $3,999
-
US $8,000US $5,999
-
US $10,000US $6,999
- ondemand_videoVideos
- 77467
-
US $6,000US $3,999
-
US $8,000US $5,999
-
US $10,000US $6,999
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc.
- Mayo Foundation for Medical Education and Research (MFMER)
- Cleveland Clinic
- Arthritis Foundation
- Healthily
- Physio.co.uk
- Sparrow Health Systems
- settingsSettings